LL-37 Inhibits TMPRSS2-Mediated S2' Site Cleavage and SARS-CoV-2 Infection but Not Omicron Variants

Abstract

Continual evolution of SARS-CoV-2 spike drives the emergence of Omicron variants that show increased spreading and immune evasion. Understanding how the variants orientate themselves towards host immune defence is crucial for controlling future pandemics. Herein, we demonstrate that human cathelicidin LL-37, a crucial component of innate immunity, predominantly binds to the S2 subunit of SARS-CoV-2 spike protein, occupying sites where TMPRSS2 typically binds. This binding impedes TMPRSS2-mediated priming at site S2' and subsequent membrane fusion processes. The mutation N764K within S2 subunit of Omicron variants reduces affinity for LL-37 significantly, thereby diminishing binding capacity and inhibitory effects on membrane fusion. Moreover, the early humoral immune response enhanced by LL-37 is observed in mice against SARS-CoV-2 spike but not Omicron BA.4/5 spike. These findings reveal the mechanism underlying interactions amongst LL-37, TMPRSS2 and SARS-CoV-2 and VOCs, and highlight the distinct mutation for Omicron variants to evade the fusion activity inhibition by host innate immunity.

Keywords

LL-37 / omicron variants / SARS-CoV-2 infection / spike protein / TMPRSS2

References

[1] S. Luo, J. Zhang, A. J. B. Kreutzberger, et al., “An Antibody From Single Human VH-Rearranging Mouse Neutralizes all SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion,” Science Immunology 7, no. 76 (2022): eadd5446.

[2] Q. Wang, Y. Guo, S. Iketani, et al., “Antibody Evasion by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4 and BA.5,” Nature 608, no. 7923 (2022): 603–608.

[3] B. Ju, H. Guo, M. Wang, et al., “Striking Antibody Evasion of SARS-CoV-2 Omicron Sub-Lineages BQ.1.1, XBB.1 and CH.1.1,” National Science Review 10, no. 8 (2023): nwad148.

[4] M. Hoffmann, H. Kleine-Weber, S. Schroeder, et al., “SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor,” Cell 181, no. 2 (2020): 271–280.e8.

[5] D. Asarnow, B. Wang, W.-H. Lee, et al., “Structural Insight Into SARS-CoV-2 Neutralizing Antibodies and Modulation of Syncytia,” Cell 184, no. 12 (2021): 3192–3204.e16.

[6] V. Calvaresi, A. G. Wrobel, J. Toporowska, et al., “Structural Dynamics in the Evolution of SARS-CoV-2 Spike Glycoprotein,” Nature Communications 14, no. 1 (2023): 1421.

[7] J. M. Taft, C. R. Weber, B. Gao, et al., “Deep Mutational Learning Predicts ACE2 Binding and Antibody Escape to Combinatorial Mutations in the SARS-CoV-2 Receptor-Binding Domain,” Cell 185, no. 21 (2022): 4008–4022.e14.

[8] J. A. Plante, Y. Liu, J. Liu, et al., “Spike Mutation D614G Alters SARS-CoV-2 Fitness,” Nature 592, no. 7852 (2021): 116–121.

[9] J. Zhang, Y. Cai, T. Xiao, et al., “Structural Impact on SARS-CoV-2 Spike Protein by D614G Substitution,” Science 372, no. 6541 (2021): 525–530.

[10] J. Zhang, Y. Cai, C. L. Lavine, et al., “Structural and Functional Impact by SARS-CoV-2 Omicron Spike Mutations,” Cell Reports 39, no. 4 (2022): 110729.

[11] J.-G. Cheong, A. Ravishankar, S. Sharma, et al., “Epigenetic Memory of Coronavirus Infection in Innate Immune Cells and Their Progenitors,” Cell 186, no. 18 (2023): 3882–3902.e24.

[12] D. V. Parums, “Editorial: A Rapid Global Increase in COVID-19 Is due to the Emergence of the EG.5 (Eris) Subvariant of Omicron SARS-CoV-2,” Medical Science Monitor 29 (2023): e942244, https://doi.org/10.12659/MSM.942244.

[13] M. Hoffmann, H. Kleine-Weber, and S. Pöhlmann, “A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells,” Molecular Cell 78, no. 4 (2020): 779–784.e5.

[14] T. Tang, J. A. Jaimes, M. K. Bidon, M. R. Straus, S. Daniel, and G. R. Whittaker, “Proteolytic Activation of SARS-CoV-2 Spike at the S1/S2 Boundary: Potential Role of Proteases Beyond Furin,” ACS Infectious Diseases 7, no. 2 (2021): 264–272.

[15] M. Hoffmann, H. Hofmann-Winkler, J. C. Smith, et al., “Camostat Mesylate Inhibits SARS-CoV-2 Activation by TMPRSS2-Related Proteases and Its Metabolite GBPA Exerts Antiviral Activity,” eBioMedicine 65 (2021): 103255.

[16] T. Ou, H. Mou, L. Zhang, A. Ojha, H. Choe, and M. Farzan, “Hydroxychloroquine-Mediated Inhibition of SARS-CoV-2 Entry Is Attenuated by TMPRSS2,” PLoS Pathogens 17, no. 1 (2021): e1009212.

[17] A. Bayati, R. Kumar, V. Francis, and P. S. McPherson, “SARS-CoV-2 Infects Cells After Viral Entry via Clathrin-Mediated Endocytosis,” Journal of Biological Chemistry 296 (2021): 100306.

[18] W. Li, M. J. Moore, N. Vasilieva, et al., “Angiotensin-Converting Enzyme 2 Is a Functional Receptor for the SARS Coronavirus,” Nature 426, no. 6965 (2003): 450–454.

[19] J. Buchrieser, J. Dufloo, M. Hubert, et al., “Syncytia Formation by SARS-CoV-2-Infected Cells,” EMBO Journal 39, no. 23 (2020): e106267.

[20] R. Bussani, E. Schneider, L. Zentilin, et al., “Persistence of Viral RNA, Pneumocyte Syncytia and Thrombosis Are Hallmarks of Advanced COVID-19 Pathology,” eBioMedicine 61 (2020): 103104.

[21] L. Braga, H. Ali, I. Secco, et al., “Drugs That Inhibit TMEM16 Proteins Block SARS-CoV-2 Spike-Induced Syncytia,” Nature 594, no. 7861 (2021): 88–93.

[22] M. M. Rajah, M. Hubert, E. Bishop, et al., “SARS-CoV-2 Alpha, Beta, and Delta Variants Display Enhanced Spike-Mediated Syncytia Formation,” EMBO Journal 40, no. 24 (2021): e108944.

[23] B. Meng, A. Abdullahi, I. A. T. M. Ferreira, et al., “Altered TMPRSS2 Usage by SARS-CoV-2 Omicron Impacts Infectivity and Fusogenicity,” Nature 603, no. 7902 (2022): 706–714.

[24] L. G. Thorne, M. Bouhaddou, A.-K. Reuschl, et al., “Evolution of Enhanced Innate Immune Evasion by SARS-CoV-2,” Nature 602, no. 7897 (2022): 487–495.

[25] S. Pfaender, K. B. Mar, E. Michailidis, et al., “LY6E Impairs Coronavirus Fusion and Confers Immune Control of Viral Disease,” Nature Microbiology 5, no. 11 (2020): 1330–1339.

[26] S. Wang, W. Li, H. Hui, et al., “Cholesterol 25-Hydroxylase Inhibits SARS-CoV-2 and Other Coronaviruses by Depleting Membrane Cholesterol,” EMBO Journal 39, no. 21 (2020): e106057.

[27] K. Shilagardi, E. D. Spear, R. Abraham, D. E. Griffin, and S. Michaelis, “The Integral Membrane Protein ZMPSTE24 Protects Cells From SARS-CoV-2 Spike-Mediated Pseudovirus Infection and Syncytia Formation,” MBio 13, no. 5 (2022): e0254322.

[28] M. S. Mousavi Maleki, M. Rostamian, and H. Madanchi, “Antimicrobial Peptides and Other Peptide-Like Therapeutics as Promising Candidates to Combat SARS-CoV-2,” Expert Review of Anti-Infective Therapy 19, no. 10 (2021): 1205–1217.

[29] M. Stravalaci, I. Pagani, E. M. Paraboschi, et al., “Recognition and Inhibition of SARS-CoV-2 by Humoral Innate Immunity Pattern Recognition Molecules,” Nature Immunology 23, no. 2 (2022): 275–286.

[30] L. Sun, W. Wang, W. Xiao, and H. Yang, “The Roles of Cathelicidin LL-37 in Inflammatory Bowel Disease,” Inflammatory Bowel Diseases 22, no. 8 (2016): 1986–1991.

[31] S. Tripathi, G. Wang, M. White, L. Qi, J. Taubenberger, and K. L. Hartshorn, “Antiviral Activity of the Human Cathelicidin, LL-37, and Derived Peptides on Seasonal and Pandemic Influenza A Viruses,” PLoS One 10, no. 4 (2015): e0124706.

[32] M. Keutmann, G. Hermes, D. Meinberger, et al., “The Ratio of Serum LL-37 Levels to Blood Leucocyte Count Correlates With COVID-19 Severity,” Scientific Reports 12, no. 1 (2022): 9447.

[33] K. M. Aloul, J. E. Nielsen, E. B. Defensor, et al., “Upregulating Human Cathelicidin Antimicrobial Peptide LL-37 Expression May Prevent Severe COVID-19 Inflammatory Responses and Reduce Microthrombosis,” Frontiers in Immunology 13 (2022): 880961.

[34] T. Bhatt, B. Dam, S. U. Khedkar, et al., “Niacinamide Enhances Cathelicidin Mediated SARS-CoV-2 Membrane Disruption,” Frontiers in Immunology 14 (2023): 1255478.

[35] M. S. Gönen, M. Alaylıoğlu, E. Durcan, et al., “Rapid and Effective Vitamin D Supplementation May Present Better Clinical Outcomes in COVID-19 (SARS-CoV-2) Patients by Altering Serum INOS1, IL1B, IFNg, Cathelicidin-LL37, and ICAM1,” Nutrients 13, no. 11 (2021): 4047.

[36] D. Li, P. Chen, T. Shi, A. Mehmood, and J. Qiu, “HD5 and LL-37 Inhibit SARS-CoV and SARS-CoV-2 Binding to Human ACE2 by Molecular Simulation,” Interdisciplinary Sciences: Computational Life Sciences 13, no. 4 (2021): 766–777.

[37] A. Roth, S. Lütke, D. Meinberger, et al., “LL-37 Fights SARS-CoV-2: The Vitamin D-Inducible Peptide LL-37 Inhibits Binding of SARS-CoV-2 Spike Protein to Its Cellular Receptor Angiotensin Converting Enzyme 2 in Vitro,” bioRxiv 2020 (2020): 408153.

[38] H. Gu, Q. Chen, G. Yang, et al., “Adaptation of SARS-CoV-2 in BALB/c Mice for Testing Vaccine Efficacy,” Science 369, no. 6511 (2020): 1603–1607.

[39] L. Bao, W. Deng, B. Huang, et al., “The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice,” Nature 583, no. 7818 (2020): 830–833.

[40] F.-L. Liu, K. Wu, J. Sun, et al., “Rapid Generation of ACE2 Humanized Inbred Mouse Model for COVID-19 With Tetraploid Complementation,” National Science Review 8, no. 2 (2021): nwaa285.

[41] C. Wang, S. Wang, D. Li, et al., “Human Cathelicidin Inhibits SARS-CoV-2 Infection: Killing Two Birds With One Stone,” ACS Infectious Diseases 7, no. 6 (2021): 1545–1554.

[42] K. B. Lokhande, T. Banerjee, K. V. Swamy, P. Ghosh, and M. Deshpande, “An In Silico Scientific Basis for LL-37 as a Therapeutic for Covid-19,” Proteins 90, no. 5 (2022): 1029–1043, https://doi.org/10.1002/prot.26198.

[43] L. B. Shrestha, C. Foster, W. Rawlinson, N. Tedla, and R. A. Bull, “Evolution of the SARS-CoV-2 Omicron Variants BA.1 to BA.5: Implications for Immune Escape and Transmission,” Reviews in Medical Virology 32, no. 5 (2022): e2381.

[44] A. de Miguel Catalina, E. Forbrig, J. Kozuch, et al., “The C-Terminal VPRTES Tail of LL-37 Influences the Mode of Attachment to a Lipid Bilayer and Antimicrobial Activity,” Biochemistry 58, no. 19 (2019): 2447–2462, https://doi.org/10.1021/acs.biochem.8b01297.

[45] S. Yu, X. Zheng, B. Zhou, et al., “SARS-CoV-2 Spike Engagement of ACE2 Primes S2' Site Cleavage and Fusion Initiation,” Proceedings of the National Academy of Sciences of the United States of America 119, no. 1 (2022): e2111199119.

[46] R. Zang, M. F. Gomez Castro, B. T. McCune, et al., “TMPRSS2 and TMPRSS4 Promote SARS-CoV-2 Infection of Human Small Intestinal Enterocytes,” Science Immunology 5, no. 47 (2020): eabc3582, https://doi.org/10.1126/sciimmunol.abc3582.

[47] S. Matsuyama, N. Nagata, K. Shirato, M. Kawase, M. Takeda, and F. Taguchi, “Efficient Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein by the Transmembrane Protease TMPRSS2,” Journal of Virology 84, no. 24 (2010): 12658–12664.

[48] B. J. Fraser, S. Beldar, A. Seitova, et al., “Structure and Activity of Human TMPRSS2 Protease Implicated in SARS-CoV-2 Activation,” Nature Chemical Biology 18, no. 9 (2022): 963–971.

[49] J. D. Gunst, N. B. Staerke, M. H. Pahus, et al., “Efficacy of the TMPRSS2 Inhibitor Camostat Mesilate in Patients Hospitalized With Covid-19-a Double-Blind Randomized Controlled Trial,” EClinicalMedicine 35 (2021): 100849.

[50] M. Yamamoto, J. Gohda, A. Kobayashi, et al., “Metalloproteinase-Dependent and TMPRSS2-Independent Cell Surface Entry Pathway of SARS-CoV-2 Requires the Furin Cleavage Site and the S2 Domain of Spike Protein,” MBio 13, no. 4 (2022): e0051922.

[51] J. V. Harte, S. L. Wakerlin, A. J. Lindsay, J. V. McCarthy, and C. Coleman-Vaughan, “Metalloprotease-Dependent S2'-Activation Promotes Cell-Cell Fusion and Syncytiation of SARS-CoV-2,” Viruses 14, no. 10 (2022): 2094, https://doi.org/10.3390/v14102094.

[52] S. Lukassen, R. L. Chua, T. Trefzer, et al., “SARS-CoV-2 Receptor ACE2 and TMPRSS2 Are Primarily Expressed in Bronchial Transient Secretory Cells,” EMBO Journal 39, no. 10 (2020): e105114.

[53] C. G. K. Ziegler, S. J. Allon, S. K. Nyquist, et al., “SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets Across Tissues,” Cell 181, no. 5 (2020): 1016–1035.e19.

[54] W. Sungnak, N. Huang, C. Bécavin, et al., “SARS-CoV-2 Entry Factors Are Highly Expressed in Nasal Epithelial Cells Together With Innate Immune Genes,” Nature Medicine 26, no. 5 (2020): 681–687, https://doi.org/10.1038/s41591-020-0868-6.

[55] H. Limburg, A. Harbig, D. Bestle, et al., “TMPRSS2 Is the Major Activating Protease of Influenza A Virus in Primary Human Airway Cells and Influenza B Virus in Human Type II Pneumocytes,” Journal of Virology 93, no. 21 (2019): 10–1128.

[56] E. Böttcher, T. Matrosovich, M. Beyerle, H.-D. Klenk, W. Garten, and M. Matrosovich, “Proteolytic Activation of Influenza Viruses by Serine Proteases TMPRSS2 and HAT From Human Airway Epithelium,” Journal of Virology 80, no. 19 (2006): 9896–9898.

[57] T. Shapira, I. A. Monreal, S. P. Dion, et al., “A TMPRSS2 Inhibitor Acts as a Pan-SARS-CoV-2 Prophylactic and Therapeutic,” Nature 605, no. 7909 (2022): 340–348.

[58] L. Wettstein, P. M. Knaff, C. Kersten, et al., “Peptidomimetic Inhibitors of TMPRSS2 Block SARS-CoV-2 Infection in Cell Culture,” Communications Biology 5, no. 1 (2022): 681.

[59] L. Wettstein, T. Weil, C. Conzelmann, et al., “Alpha-1 Antitrypsin Inhibits TMPRSS2 Protease Activity and SARS-CoV-2 Infection,” Nature Communications 12, no. 1 (2021): 1726.

[60] Y. Chen, T. B. Lear, J. W. Evankovich, et al., “A High-Throughput Screen for TMPRSS2 Expression Identifies FDA-Approved Compounds That Can Limit SARS-CoV-2 Entry,” Nature Communications 12, no. 1 (2021): 3907.

[61] S. C. Mansour, O. M. Pena, and R. E. W. Hancock, “Host defense peptides: front-line immunomodulators,” Trends in Immunology 35, no. 9 (2014): 443–450.

[62] G. Wang, “Human Antimicrobial Peptides and Proteins,” Pharmaceuticals 7, no. 5 (2014): 545–594.

[63] M. R. Scheenstra, R. M. van Harten, E. J. A. Veldhuizen, H. P. Haagsman, and M. Coorens, “Cathelicidins Modulate TLR-Activation and Inflammation,” Frontiers in Immunology 11 (2020): 1137.

[64] R. Lande, J. Gregorio, V. Facchinetti, et al., “Plasmacytoid Dendritic Cells Sense Self-DNA Coupled With Antimicrobial Peptide,” Nature 449, no. 7162 (2007): 564–569.

[65] D. Singh, R. Qi, J. L. Jordan, L. San Mateo, and C. C. Kao, “The Human Antimicrobial Peptide LL-37, but Not the Mouse Ortholog, mCRAMP, Can Stimulate Signaling by Poly(I:C) Through a FPRL1-Dependent Pathway,” Journal of Biological Chemistry 288, no. 12 (2013): 8258–8268, https://doi.org/10.1074/jbc.M112.440883.

[66] Z. Zhang, G. Cherryholmes, F. Chang, D. M. Rose, I. Schraufstatter, and J. E. Shively, “Evidence That Cathelicidin Peptide LL-37 May Act as a Functional Ligand for CXCR2 on Human Neutrophils,” European Journal of Immunology 39, no. 11 (2009): 3181–3194.

[67] S. Tripathi, G. Wang, M. White, M. Rynkiewicz, B. Seaton, and K. Hartshorn, “Identifying the Critical Domain of LL-37 Involved in Mediating Neutrophil Activation in the Presence of Influenza Virus: Functional and Structural Analysis,” PLoS One 10, no. 8 (2015): e0133454.

[68] N. Mookherjee, K. L. Brown, D. M. E. Bowdish, et al., “Modulation of the TLR-Mediated Inflammatory Response by the Endogenous Human Host Defense Peptide LL-37,” Journal of Immunology 176, no. 4 (2006): 2455–2464.

[69] Y. Cao, J. Wang, F. Jian, et al., “Omicron Escapes the Majority of Existing SARS-CoV-2 Neutralizing Antibodies,” Nature 602, no. 7898 (2022): 657–663.

[70] R. Suzuki, D. Yamasoba, I. Kimura, et al., “Attenuated Fusogenicity and Pathogenicity of SARS-CoV-2 Omicron Variant,” Nature 603, no. 7902 (2022): 700–705.

[71] I. Kimura, D. Yamasoba, T. Tamura, et al., “Virological Characteristics of the SARS-CoV-2 Omicron BA.2 Subvariants, Including BA.4 and BA.5,” Cell 185, no. 21 (2022): 3992–4007.e16.

[72] J. Yang, W. Wang, Z. Chen, et al., “A Vaccine Targeting the RBD of the S Protein of SARS-CoV-2 Induces Protective Immunity,” Nature 586, no. 7830 (2020): 572–577.

[73] T. F. Rogers, F. Zhao, D. Huang, et al., “Isolation of Potent SARS-CoV-2 Neutralizing Antibodies and Protection From Disease in a Small Animal Model,” Science 369, no. 6506 (2020): 956–963.

[74] H. Cho, K. K. Gonzales-Wartz, D. Huang, et al., “Bispecific Antibodies Targeting Distinct Regions of the Spike Protein Potently Neutralize SARS-CoV-2 Variants of Concern,” Science Translational Medicine 13, no. 616 (2021): eabj5413.

[75] C. Dacon, C. Tucker, L. Peng, et al., “Broadly Neutralizing Antibodies Target the Coronavirus Fusion Peptide,” Science 377, no. 6607 (2022): 728–735.

[76] A. Tauzin, A. Nicolas, S. Ding, et al., “Spike Recognition and Neutralization of SARS-CoV-2 Omicron Subvariants Elicited After the Third Dose of mRNA Vaccine,” Cell Reports 42, no. 1 (2023): 111998.

[77] G. Liu, W. Du, X. Sang, et al., “RNA G-Quadruplex in TMPRSS2 Reduces SARS-CoV-2 Infection,” Nature Communications 13, no. 1 (2022): 1444.

[78] M. Liao, Y. Liu, J. Yuan, et al., “Single-Cell Landscape of Bronchoalveolar Immune Cells in Patients With COVID-19,” Nature Medicine 26, no. 6 (2020): 842–844.

[79] X. Wei, B. Shao, Z. He, et al., “Cationic Nanocarriers Induce Cell Necrosis Through Impairment of Na(+)/K(+)-ATPase and Cause Subsequent Inflammatory Response,” Cell Research 25, no. 2 (2015): 237–253.

RIGHTS & PERMISSIONS

2025 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.